Nos últimos dez anos, observamos um crescimento exponencial de agentes
anticoagulantes e antiagregantes plaquetários desenvolvidos para uso clínico, com intuito …

SciELO - Brasil - Diretrizes brasileiras de antiagregantes plaquetários e anticoagulantes em
cardiologia Diretrizes brasileiras de antiagregantes plaquetários e anticoagulantes em …

Atherothrombosis and its complications are currently the leading cause of worldwide
mortality and its incidence is increasing. Platelets play an essential role in the pathogenesis …

Objective Oral direct thrombin and anti-Xa inhibitors have been shown to be efficacious in
the prevention and treatment of venous thromboembolism, and prevention of embolic events …

Drugs interfering with blood coagulation are a mainstay of cardiovascular therapy. Despite
their widespread use, there are a number of unmet needs for current parenteral and oral …

This chapter focuses on new antithrombotic drugs that are in phase II or III clinical testing.
Development of these new agents was prompted by limitations of existing antiplatelet …

This article focuses on new antithrombotic drugs that are in or are entering phase 3 clinical
testing. Development of these new agents was prompted by the limitations of existing …

Coronary atherothrombotic disease, including chronic stable angina and acute coronary
syndromes (ACS), is associated with significant global burden. The acute clinical …

Antithrombotic agents are the cornerstones of therapy for thrombosis. The compositions of
arterial and venous clots differ, rendering antiplatelet agents more effective for arterial …

Thrombosis, an important complication of atherosclerosis and of various medical and
surgical conditions, can be prevented or treated effectively by a variety of pharmacologic …